Severe Malaria: Bridging the Wait for IV Artesunate
A returning traveler with cerebral and renal involvement from severe P. falciparum malaria, at a hospital with no IV artesunate on site. The disagreement isn't about whether he needs the drug — it's about whether oral bridging therapy can be trusted in a patient whose gut perfusion may already be compromised, or whether everything should ride on transfer instead.
D.O., a 45-year-old man, drives long-haul freight between Chicago and Atlanta most weeks of the year, and had been home only three days from his first trip back to Lagos in over a decade — booked on four days' notice for his father's funeral, with no window on the calendar for a travel clinic visit and no chemoprophylaxis started — when the fevers began. He is exactly the kind of traveler the surveillance data keeps naming as highest-risk: someone visiting friends and relatives in a malaria-endemic country of origin, who often reasonably feels the destination doesn't call for the same precautions a tourist would take. He treated the first two days as jet lag and a head cold, working through a low-grade temperature he blamed on the flight, and only came to the emergency department when his wife found him unable to say what day it was.
By the time the thick smear came back positive for Plasmodium falciparum, the parasitemia already sat at 8.1%, and the confusion was not simple fatigue: he could not follow a two-step command, and his Glasgow Coma Scale had fallen to 12. His creatinine, drawn on the same panel with no known baseline to compare against, came back at 2.4 mg/dL — cerebral involvement and acute kidney injury both present, either one alone enough to make this severe malaria rather than the uncomplicated infection his own flu self-diagnosis had assumed. The hospital pharmacy, called the moment the smear resulted, confirmed what the treating physician already suspected: no IV artesunate on site, and no local wholesaler carrying it as a routinely stocked item. The drug occupies a strange middle space in American practice — the same artesunate that SEAQUAMAT and AQUAMAT together established, over a decade ago, as the reason severe malaria mortality dropped in the first place, fully FDA-approved and commercially available since 2020, and still rare enough that most hospitals outside the largest academic centers keep none of it on the shelf. IV quinidine gluconate, the parenteral fallback an older training generation would reach for by reflex, is no longer manufactured in the United States at all; production stopped years ago, and no other company picked it up. Whatever D.O. receives in the next several hours, it will not be that.
Six hours from the nearest confirmed dose
Start the interim oral regimen now, by NG tube, and start artemether-lumefantrine specifically — not atovaquone-proguanil, not quinine. CDC names artemether-lumefantrine as the preferred interim oral agent for exactly one reason, and it is the reason that matters at this hour: its onset of action is the fastest of the options we have. That guidance exists precisely because the two trials that established artesunate's benefit in the first place — SEAQUAMAT in Southeast Asian adults and AQUAMAT in African children — both found that the single biggest determinant of survival in severe malaria is how quickly effective antiparasitic drug exposure begins, not which specific route delivered it. Atovaquone-proguanil is a listed alternative and I'd give it if we had nothing else, but choosing the slower drug in a patient whose problem is that time has already run long would be an odd way to act on that finding.
Quinidine gluconate isn't quietly on back order somewhere either — it stopped being manufactured in this country years ago. There is no parenteral fallback sitting in a cabinet we haven't checked. Oral is not the second-best option tonight; for the next several hours, it's the only drug actually in the building.
You're right that delay is the dominant driver here — I'm not disputing the trial data or the protocol in the abstract. What I don't trust is applying an absorption assumption built on the general severe-malaria population to a patient who is already showing us reduced end-organ perfusion. A GCS of 12 and a creatinine with no baseline to compare against are exactly the findings that make me doubt his splanchnic blood flow is doing its usual job right now.
An NG dose we can't verify landed in his bloodstream isn't a real bridge, it's a documentation exercise that makes the chart look like treatment started. I want that transfer call going out in the next fifteen minutes, not after we've watched an oral dose we can't confirm worked.
There's a version of this that doesn't require either of you to be right about his gut. Give the NG dose now and call the transfer center in the same five minutes — those two things were never actually in tension, and treating them as sequential is the only genuinely avoidable delay left in this case. The real question isn't bridge-or-transfer, it's how hard we push the transport team to move a GCS-12 patient with a soft blood pressure.
Unverified absorption is a real limitation, not a reason to wait on the one intervention we can start in this room in the next five minutes. I'll have both tracks moving before the pharmacy finishes drawing up the artemether-lumefantrine.
Agreed within minutes, once the emergency physician reframed it: artemether-lumefantrine started by NG tube immediately, the CDC Malaria Hotline called for real-time guidance, and transfer to the nearest artesunate-stocked academic center activated in parallel rather than held in reserve as a fallback.
Not agreed: how long to wait on the two-hour mental-status and parasitemia recheck before escalating transfer from urgent to emergent. The critical care physician wanted the transport team wheels-up within the hour regardless of any early response to the oral dose, arguing that a GCS-12 patient's trajectory can turn before any lab recheck would catch it. The infectious disease physician wanted the two-hour recheck first, since real early improvement would reasonably lower the transfer urgency without eliminating the need for it outright. Neither view was overruled; both physicians left the bedside tracking the same two-hour mark as the actual pivot point, with different thresholds for what it would take to change their minds.